Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms

Sci Rep. 2023 Jul 31;13(1):12395. doi: 10.1038/s41598-023-38904-1.

Abstract

Migraine is a common, polygenic disorder that is characterized by moderate to severe headache attacks. Migraine attacks are commonly treated with triptans, i.e. serotonin receptor agonists. However, triptans are effective in ~ 60% of the population, and the mechanisms of triptans are debated. Here, we aim to expose the mechanisms of triptan using metabolomics and transcriptomics in spontaneous migraine attacks. We collected temporal multi-omics profiles on 24 migraine patients, using samples collected at a migraine attack, 2 h after treatment with a triptan, when headache-free, and after a cold-pressor test. Differential metabolomic analysis was performed to find metabolites associated with treatment. Their effect was further investigated using correlation analysis and a machine learning approach. We found three differential metabolites: cortisol, sumatriptan and glutamine. The change in sumatriptan levels correlated with a change in GNAI1 and VIPR2 gene expression, both known to regulate cAMP levels. Furthermore, we found fatty acid oxidation to be affected, a mechanism known to be involved in migraine but not previously found in relation to triptans. In conclusion, using an integrative approach we find evidence for a role of glutamine, cAMP regulation, and fatty acid oxidation in the molecular mechanisms of migraine and/or the effect of triptans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fatty Acids
  • Glutamine
  • Humans
  • Migraine Disorders* / drug therapy
  • Migraine Disorders* / genetics
  • Multiomics
  • Serotonin 5-HT1 Receptor Agonists
  • Sumatriptan / therapeutic use
  • Tryptamines* / therapeutic use

Substances

  • Tryptamines
  • Sumatriptan
  • Glutamine
  • Serotonin 5-HT1 Receptor Agonists
  • Fatty Acids